Biotech vs AI vs Climate Tech: How Research Momentum Differs Across the Three Largest Innovation Verticals

Not all research momentum looks the same. AI, biotech, and climate tech collectively account for the majority of preprint volume tracked by the Finch Innovation Index, but the shape, pace, and geographic distribution of that output differ in ways that carry direct implications for investment timing and portfolio allocation.

Treating these three verticals as interchangeable "innovation bets" is a category error. Each one operates on a distinct publication cadence, follows different commercialization pathways, and responds to different external accelerants. Here is what the structural differences look like and why they matter.

Publication Volume and Acceleration Rates

AI research dominates raw preprint volume. Across repositories like arXiv, AI-adjacent themes consistently produce the highest monthly paper counts of any vertical tracked in the Finch Innovation Index. AI-related preprint volume has grown at roughly 25 to 30 percent annually over the past five years. This growth is not evenly distributed across sub-themes; large language models and generative architectures have absorbed a disproportionate share of the acceleration since 2022, while older sub-fields like computer vision have plateaued or decelerated.

Biotech preprint growth runs at a slower absolute pace but shows higher thematic diversity. Platforms like bioRxiv and medRxiv host research across dozens of sub-verticals, from gene editing to synthetic biology to computational drug discovery. Biotech preprint output spans more distinct sub-themes than AI or climate tech within the Finch Innovation Index. This breadth means that momentum spikes in any single biotech sub-theme are less likely to distort the vertical-level signal.

Climate tech sits in a different position entirely. Climate tech preprint volume is smaller than AI or biotech but has the fastest acceleration rate among the three verticals since 2020. Themes like solid-state batteries, green hydrogen, carbon capture, and advanced photovoltaics have all shown sustained upward trajectories. For investors screening early-stage opportunities, momentum scoring across these themes reveals which climate sub-verticals are building research density ahead of commercial scale-up.

Geographic Concentration and What It Signals

The geographic fingerprint of each vertical tells a different story about where commercialization is likely to concentrate.

AI research output is heavily concentrated in the United States and China, with those two countries producing the majority of high-impact preprints. AI research is more geographically concentrated than either biotech or climate tech, with the US and China together accounting for a dominant share of output. This bipolar structure has direct implications for where AI startups form and where corporate R&D investment flows. For a deeper look at these patterns, see our analysis of geographic concentration in AI research.

Biotech research is more geographically distributed. Europe, particularly the UK, Germany, and Switzerland, produces a significant share of biotech preprints. Biotech research geography is notably distributed, with strong clusters in Europe and East Asia alongside North America. South Korea and Japan contribute meaningfully in areas like cell therapy and biomaterials.

Climate tech research shows the most even geographic distribution of the three verticals. Climate tech research output is the most geographically distributed of the three verticals, with meaningful contributions from Europe, East Asia, and the Middle East. Sovereign wealth funds in particular should note that research density in regions like the Gulf states on topics such as green hydrogen often precedes large-scale capital deployment.

Commercialization Lag and the Signal Window

The gap between research momentum and commercial traction varies dramatically across these verticals.

AI has the shortest research-to-product cycle of the three verticals, often under two years. A technique published on arXiv in January can appear in a production API by December. This compresses the signal advantage that preprints provide, but does not eliminate it; the Finch Innovation Index still captures sub-theme acceleration patterns 12 to 18 months before venture funding rounds cluster around them.

Biotech operates on a much longer timeline. Regulatory requirements, clinical trials, and manufacturing scale-up mean that biotech research signals typically lead commercial outcomes by three to seven years. Biotech's research-to-commercialization lag of three to seven years is the longest among the three major innovation verticals. This longer window actually increases the value of early momentum detection for long-horizon allocators.

Climate tech falls between the two. Hardware-intensive climate sub-themes like battery chemistry carry longer development cycles than software-adjacent ones like grid optimization. Climate tech commercialization timelines range from two to five years depending on whether the sub-theme is hardware-intensive or software-adjacent. This heterogeneity within the vertical means that a single momentum score for "climate tech" obscures important sub-theme variation.

What This Means for Portfolio Construction

The structural differences across these three verticals argue against uniform allocation strategies. AI momentum signals demand faster response times and shorter hold assumptions. Biotech signals reward patient capital with the discipline to act on research trends years before market consensus forms. Climate tech requires sub-theme-level granularity to distinguish between near-term deployment plays and longer-horizon technology bets.

The Finch Innovation Index tracks all three verticals across its 73 investable themes, providing the sub-theme resolution needed to move beyond vertical-level generalizations. For allocators building portfolios across innovation verticals, the question is not which vertical has the most momentum, but which sub-themes within each vertical are accelerating at rates that signal impending commercial inflection.